A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Research: Shared Services

Pathology and Biorepository Publications

 

Ask the Expert

Dr. Edelman’s Bio Image

Get answers to your Medical oncology for lung cancer questions.

Dr. Edelman’s Bio | Q&A Archive

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

 

The Tissue Bank facility has provided support for a number of research projects. Selected publications are listed.

  1. Yang H, Linnoila R, Conrad N, Krasna M, Aisner S, Johnson B, Kelley M: “TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract,” International Journal of Cancer, 64:229-233, 1995.


  2. Souza, R.F., Appel, R., Yin, J., Wang, S., Smolinski, K.N., Abraham, J.M., Zou, T-T., Shi, YQ., Lei, J., Cottrell, J., Cymes, K., Biden, K., Simms, L., Leggett, B., Lynch, P.M., Frazier, M., Powell, S.M., Harpaz, N., Sugimura, H., Young, J., and Meltzer, S.J.: Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumors. Nature Genetics 14: 255-257, 1996.


  3. Souza, R.F., Garrigue-Antar, L. Lei, J., Yin, J., Appel, R., Vellucci, V.F., Zou, T-T., Zhou, X., Wang, S., Rhyu, M-G., Cymes, K., Chan, O., Park, W-S., Krasna, M.J., Greenwald, B.D., Cottrell, J., Abraham, J. M., Simms, L., Leggett, B., Young, J., Harpaz, N., Reiss, M., and Meltzer, S.J.: Alterations of transforming growth factor-B1 receptor type II occur in ulcerative colitis-associated carcinomas, sporadic colorectal neoplasms, and esophageal carcinomas, but not in gastric neoplasms. Hum Cell. 9:229-236, 1996.


  4. Souza, R.F., Lei, J., Yin, J., Appel, R., Zou, T-T., Zhou, X., Wang, S., Rhyu, M-G., Cymes,K., Chan, O., Park,W-S.,Krasna, M.J., Greenwald, B.D., Cottrell, J.,Abraham, J.M., Simms, L., Leggett, B., Young, J., Harpaz, N., Meltzer, S.J.: A transforming growth factor-B 1 receptor type II mutation in ulcerative colitis-associated neoplasms. Gastroenterology 112: 40-45, 1997.


  5. Souza, R.F., Yin, J., Smolinski, K.N., Zou, T.T., Wang, S., Shi, Y.Q., Rhyu, M.G., Cottrell, J., Abraham ,J.M., Biden, K., Simms, L., Leggett, B., Bova, G.S., Frank, T., Powell, S.M., Sugimura, H., Young, J., Harpaz, N., Shimizu, K., Matsubara, N., and Meltzer, S.J.: Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors. Cancer Res. 57:2350-2353, 1997.


  6. Cawley, H.M., Meltzer, S.J., De Benedetti, V.M.G., Hollstein, M. C., Meuhlbauer, K-R., Liang, L., Bennett, W.P., Souza, R.F., Greenwald, B.D., Cottrell, J., Salabes, A., Bartsch, H., and Trivers, G.E.: Anti-p53 antibodies in patients with Barrett’s esophagus or esophageal carcinoma can predate cancer diagnosis. Gastroenterology 115: 19-27, 1998.


  7. Simms LA, Radford-Smith G, Biden KG, Buttenshaw R, Cummings M, Jass JR, Young J, Meltzer SJ, Leggett BA. Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. Oncogene, 17:2003-2008; 1998.


  8. Krasna, M. J., Mao, Y.S., Sonett, J.R., Tamura, G., Jones, R., Suntharalingam, M., and Meltzer, S.J.: p53 gene protein overexpression predicts results of trimodality therapy in esophageal cancer patients. Ann. Thorac. Surg. 68:2021-2025, 1999.


  9. Dunn J, Garde J, Dolan K, Gosney JR, Sutton R, Meltzer SJ, Field JK. Multiple target sites of allelic imbalance on chromosome 17 in Barrett’s esophageal cancer. Oncogene, 18:987-994; 1999.


  10. Biden K, Simms L, Cummings M, Buttenshaw R, Schoch E, Searle J, Gobe G, Jass J, Meltzer SJ,Leggett BA, Young J. Expression of Bcl-2 protein is decreased in colorectal adenocarcinomas with microsatellite instability. Oncogene, 18:1245-1249; 1999.


  11. Jass JR, Biden KG, Cummings M, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, Leggett BA. Characterization of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J. Clin. Pathol., 52:455-460. 1999.


  12. Sheikh MS, Huang Y, Fernandez-Salas EA, El-Deiry WS, Amundson S, Meltzer SJ, Yin J, Holbrook NJ, Fornace AJ. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene and is overexpressed in primary tumors of the gastrointestinal tract. Oncogene, 18:4153-4159; 1999.


  13. Kawakami K, Brabender J, Lord R, Groshen S, Greenwald B, Krasna MJ, Yin J, Fleisher AS, Abraham JM, Beer D, Sidransky D, Huss H, Demeester T, Eads C, Laird P, Ilson D, Kelsen D, Harpole D, Moore M, Dunenberg K, Danenberg P, Meltzer S: "Hypermethylated APC DNA in plasma and prognosis of patients with esopahgeal adenocarcinoma,” Journal National Cancer Institute, 92;22:1805-1811, November 15, 2000.


  14. Jiao X, Zhang M, Wen Z, Krasna MJ: “Pleural lavage cytology in esophageal cancer without pleural effusions: clinicopathologic analysis,” Proceedings of American Society of Clinical Oncology, Journal of Cardiovascular and Thoracic Surgery, 17:575-579, 2000.


  15. Simms LA, Young J, Wicking C, Meltzer SJ, Jass Jr, Leggett BA. The apoptotic regulatory gene, BCL10, is mutated in sporadic mismatch repair deficient colorectal cancers. Cell Death Diff., 7:236-237; 2000.


  16. Karp, J.E., Lancet, J.E., Kaufmann, S.H., End, D.W., Wright, J.J., Bol, K., Horak, I., Tidwell, M.L., Liesveld, J., Kottke, T.J., Ange, D., Buddharaju, L., Gojo, I., Highsmith, W.E., Belly, R.T., Hohl, R.T., Rybak, M.E., Thibault, A., Rosenblatt, J. Clinical and Biological activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapse acute leukemias: A phase I clinical-laboratory correlative trial. Blood 97:3361-3369, 2001.


  17. Jiao X, Krasna MJ: "Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology," Annals of Thoracic Surgery, 74:287-284, 2002.


  18. Krasna MJ, Jiao X, Sonett J, Gamliel Z, Eslami A, Rafaely Y, Mao Y: “Thoracoscopic/laparoscopic lymph node staging in esophageal cancer: Do clinicopathological factors affect the outcome?” Annals of Thoracic Surgery, 73:1710-1713, 2002.


  19. Selaru FM, Zou T Shustova V, Xu Y, Yin J, Mori Y, Sato F, Wang S, Olaru A, Shibata D, Greenwald B, Krasna M, Abraham J, Meltzer S: “Global gene expression profiling in Barrett’s esophagus and esophageal cancer: a comparative analysis using cDNA microarrays,” Oncogene, 21:475-478, 2002.


  20. Chen X, Ning L, Wang S, Wu N, Hong J, Jiao X, Krasna MJ, Beer D, Yang CS: "Leukotriene A4 hydrolase in rat and human esophageal adenocarcinomas and inhibitory effects of Bestatin", Journal of the National Cancer Institute, 95:1053-1061, 2003.


  21. Jiao X, Eslami A, Ioffe O, Kwong K, Henry M, Zeng Q, Refaely Y, Burrows W, Gamliel Z, Krasna MJ: "Immunohistochemistry Analysis of Micrometastasis in Pretreatment Lymph Nodes from Patients with Esophageal Cancer", Annals of Thoracic Surgery, 76:996-1000,2003.


  22. Zheng Y, Loffredo C, Yu Z, Jones R, Krasna M, Alberg A, Yung R, Perlmutter D, Enewold L, Harris C, Shields P: "Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls," Carcinogenesis, 24(2):269-274, 2003.

This page was last updated on: June 12, 2012.